Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056263 · ClinicalTrials.gov registry record
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 52
- Enrollment target
NCT01056263: Completed study, sponsored by Pfizer.
NCT01056263 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01056263 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 \[NCT00076011\] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.
Primary Outcome
Overall survival is the duration from first dose of study medication to death. For participants who are alive, overall survival is censored at the last contact.
Interventions
- DRUG axitinib: observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-12 |
What the finished NCT01056263 record still lists
NCT01056263 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which axitinib: observational study is the first listed.
NCT01056263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01056263 about?
NCT01056263 is a clinical study titled "Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012". The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 \[NCT00076011\] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.
What is the current status of trial NCT01056263?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2010-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01056263?
The interventions under investigation include: axitinib: observational study (DRUG).
Who is sponsoring clinical trial NCT01056263?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia